Alessandro Hammond
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alessandro Hammond has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Bhav Jain
Stanford University School of Medicine, Stanford, California, USA
3 shared publications Cameron Sabet
Georgetown School of Medicine
3 shared publicationsKeshav Balakrishna
University of Texas at Dallas, Richardson, Texas, USA
3 shared publications- Vivaan Bhatt
Harvard University
3 shared publications - Fatima Cody Stanford
Massachusetts General Hospital, MGH Weight Center, Department of Medicine-Division of Endocrinology-Neuroendocrine, Department of Pediatrics-Division of Endocrinology, Nutrition Obesity Research Center at Harvard (NORCH), Boston, MA, USA
2 shared publications - Keshav Balakrishna
University of Texas at Dallas, Dallas, TX, USA
2 shared publications
Latest Publications
- Open Access
Multi-Model Comparison of Deep and Classical Architectures for ECG Diagnostic Superclass Classification on PTB-XL
Objective. It remains unclear which architecture best sorts 12-lead electrocardiograms into diagnostic superclasses, and whether added model complexity pays off. Methods. Using 21,375 PTB-XL records under one patient-level split, we compared a Mamba-style state space model, a residual convolutional network, a bidirectional long short-term memory network, a convolutional-recurrent network with attention, soft-voting ensembles of these networks, and MiniRocket features with LightGBM. Each record took the superclass of its highest-likelihood diagnostic code, and we scored saved predictions with paired patient-level bootstrap intervals. Results. No model clearly outperformed MiniRocket with LightGBM, which needs no graphics processor. The ensemble of the three deep models with the highest validation macro F1 score reached 0.656, against 0.645 for MiniRocket with LightGBM (difference +0.011, 95% confidence interval -0.007 to +0.031), and an ensemble of all four deep models reached 0.657. An exploratory ensemble, whose members we chose after seeing test results, reached 0.665 and was the only ensemble whose interval excluded zero (+0.021, 0.002 to 0.040); we regard that margin as optimistic. Hypertrophy was the hardest class (F1 0.33 to 0.41), and differences in its recall mostly reflected threshold placement. Conclusions. Under one shared split, deep ensembles added little over a classical pipeline. Significance. These results give biomedical informatics researchers a statistically grounded reference for judging whether complex models justify their cost on this benchmark. With one dataset, one split, one training seed per model, and no external validation, they do not show readiness for clinical use.
Open AccessMulti-Model Comparison of Deep and Classical Architectures for ECG Diagnostic Superclass Classification on PTB-XL
Objective. It remains unclear which architecture best sorts 12-lead electrocardiograms into diagnostic superclasses, and whether added model complexity pays off. Methods. Using 21,375 PTB-XL records under one patient-level split, we compared a Mamba-style state space model, a residual convolutional network, a bidirectional long short-term memory network, a convolutional-recurrent network with attention, soft-voting ensembles of these networks, and MiniRocket features with LightGBM. Each record took the superclass of its highest-likelihood diagnostic code, and we scored saved predictions with paired patient-level bootstrap intervals. Results. No model clearly outperformed MiniRocket with LightGBM, which needs no graphics processor. The ensemble of the three deep models with the highest validation macro F1 score reached 0.656, against 0.645 for MiniRocket with LightGBM (difference +0.011, 95% confidence interval -0.007 to +0.031), and an ensemble of all four deep models reached 0.657. An exploratory ensemble, whose members we chose after seeing test results, reached 0.665 and was the only ensemble whose interval excluded zero (+0.021, 0.002 to 0.040); we regard that margin as optimistic. Hypertrophy was the hardest class (F1 0.33 to 0.41), and differences in its recall mostly reflected threshold placement. Conclusions. Under one shared split, deep ensembles added little over a classical pipeline. Significance. These results give biomedical informatics researchers a statistically grounded reference for judging whether complex models justify their cost on this benchmark. With one dataset, one split, one training seed per model, and no external validation, they do not show readiness for clinical use.
- Open Access
Does Replacing SOFA-1 with SOFA-2 Change Mortality Discrimination and Calibration Across Patient Subgroups? A Paired Analysis in MIMIC-IV
Background: The Sequential Organ Failure Assessment (SOFA) score describes organ dysfunction in intensive care. SOFA-2, published in 2025, updates the 1996 score (SOFA-1). It is unknown whether the update changes mortality discrimination and calibration within patient subgroups. Methods: We analyzed 85,228 first ICU stays per hospitalization (65,354 adults) in MIMIC-IV v3.1. We scored SOFA-1 (two prespecified conventions for intubated patients) and SOFA-2 from the same data over the same first 24 hours. The primary outcome was in-hospital mortality; ICU mortality was secondary. Using a paired patient-level bootstrap (5,000 replicates), we estimated AUROC overall and by sex, race and insurance; the paired change between scores; subgroup gaps in AUROC and the change in those gaps; and descriptive calibration. The protocol was committed before any analysis relating scores to mortality. Results: In-hospital death occurred in 9,468 stays (11.1%). AUROC was 0.762 for SOFA-2, 0.743 for SOFA-1 as charted and 0.735 for SOFA-1 under the community convention; SOFA-2 minus SOFA-1 was +0.019 (+0.016 to +0.023) and +0.027 (+0.023 to +0.031). Swapping single domains showed that the respiratory domain accounted for the whole gain, about 74% of it through the SpO2/FiO2 fallback. Subgroup gaps changed against SOFA-1 as charted (male–female +0.021; White–Black +0.025), driven by the brain-domain rule, but not against the community convention. The White–Black change was not seen in patients under 65, and neither change was consistent across ICU types. Calibration differences between groups were large but changed little between scores (|Δ log O/E| ≤ 0.045). Insurance-group differences largely disappeared in patients under 65, whereas race-group differences did not. Conclusions: SOFA-2 modestly improved overall discrimination for in-hospital mortality, mainly through its respiratory domain. Changes in subgroup performance gaps were small. They depended on how SOFA-1 handles intubated patients, partly reflected age, and were not consistent across ICU types. These are descriptive associations in a single database; we draw no causal or fairness conclusions.
Open AccessDoes Replacing SOFA-1 with SOFA-2 Change Mortality Discrimination and Calibration Across Patient Subgroups? A Paired Analysis in MIMIC-IV
Background: The Sequential Organ Failure Assessment (SOFA) score describes organ dysfunction in intensive care. SOFA-2, published in 2025, updates the 1996 score (SOFA-1). It is unknown whether the update changes mortality discrimination and calibration within patient subgroups. Methods: We analyzed 85,228 first ICU stays per hospitalization (65,354 adults) in MIMIC-IV v3.1. We scored SOFA-1 (two prespecified conventions for intubated patients) and SOFA-2 from the same data over the same first 24 hours. The primary outcome was in-hospital mortality; ICU mortality was secondary. Using a paired patient-level bootstrap (5,000 replicates), we estimated AUROC overall and by sex, race and insurance; the paired change between scores; subgroup gaps in AUROC and the change in those gaps; and descriptive calibration. The protocol was committed before any analysis relating scores to mortality. Results: In-hospital death occurred in 9,468 stays (11.1%). AUROC was 0.762 for SOFA-2, 0.743 for SOFA-1 as charted and 0.735 for SOFA-1 under the community convention; SOFA-2 minus SOFA-1 was +0.019 (+0.016 to +0.023) and +0.027 (+0.023 to +0.031). Swapping single domains showed that the respiratory domain accounted for the whole gain, about 74% of it through the SpO2/FiO2 fallback. Subgroup gaps changed against SOFA-1 as charted (male–female +0.021; White–Black +0.025), driven by the brain-domain rule, but not against the community convention. The White–Black change was not seen in patients under 65, and neither change was consistent across ICU types. Calibration differences between groups were large but changed little between scores (|Δ log O/E| ≤ 0.045). Insurance-group differences largely disappeared in patients under 65, whereas race-group differences did not. Conclusions: SOFA-2 modestly improved overall discrimination for in-hospital mortality, mainly through its respiratory domain. Changes in subgroup performance gaps were small. They depended on how SOFA-1 handles intubated patients, partly reflected age, and were not consistent across ICU types. These are descriptive associations in a single database; we draw no causal or fairness conclusions.
- Open Access
Reporting of Pericardial Adverse Events with Immune Checkpoint Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System
Background. Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events in almost any organ. While myocarditis has received the most attention, data on pericardial disease with ICI use are limited. We examined pericardial adverse event reporting with nine ICIs using the FDA Adverse Event Reporting System (FAERS). Methods. We combined legacy AERS and current FAERS quarterly files from January 2011 to June 2026 into 18,629,240 unique cases, deduplicated by case number, and removed cases the FDA had listed as deleted. ICI exposure was identified from generic names, brand names, development code names and the active-ingredient field. Pericardial events were defined by seven MedDRA preferred terms. We estimated reporting odds ratios (ROR), proportional reporting ratios (PRR), Bayesian information components (IC) and empirical Bayes geometric means (EBGM). We also examined myocarditis co-reporting, time trends, a comparison with other antineoplastic agents, a MedDRA query-based outcome, and 14 alternative definitions. Results. The analysis included 18,514,045 cases: 277,434 involved an ICI, 34,792 carried a pericardial term, and 1,680 had both. Pericardial events were reported disproportionately with ICIs (ROR 3.35 (95% CI 3.19 to 3.52); PRR 3.34; IC025 1.62). Eight of nine agents had a ROR above 1 (3.32 to 5.63). Among the most frequently reported terms, estimates were highest for cardiac tamponade (5.59 (95% CI 4.98 to 6.28)), followed by pericardial effusion (3.83 (95% CI 3.60 to 4.07)) and pericarditis (2.09 (95% CI 1.89 to 2.31)). After removing cases that also reported myocarditis, the ROR was 3.13 (95% CI 2.98 to 3.30). Most sensitivity analyses gave similar estimates (ROR 3.13 to 3.47); defining exposure by generic drug names alone, which identified only 44% of exposed cases, gave 3.99. Compared with cases naming other L01 antineoplastic agents, the ROR was 1.13 (95% CI 1.08 to 1.19): 1.28 (95% CI 1.20 to 1.36) for ICI-only cases and 0.96 (95% CI 0.89 to 1.04) when another antineoplastic was also named. The ICI-specific reporting odds ratio fell each quarter (odds ratio 0.977 per quarter, 95% CI 0.973 to 0.980). Conclusions. In FAERS, pericardial events were reported more often with ICIs than with other drugs across most agents and terms; however, incidence and causation cannot be determined. The excess over other antineoplastic agents was small, and reporting disproportionality declined over time. These findings support clinical awareness of pericardial disease in patients receiving ICIs and warrant study in data that can measure incidence.
Open AccessReporting of Pericardial Adverse Events with Immune Checkpoint Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System
Background. Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events in almost any organ. While myocarditis has received the most attention, data on pericardial disease with ICI use are limited. We examined pericardial adverse event reporting with nine ICIs using the FDA Adverse Event Reporting System (FAERS). Methods. We combined legacy AERS and current FAERS quarterly files from January 2011 to June 2026 into 18,629,240 unique cases, deduplicated by case number, and removed cases the FDA had listed as deleted. ICI exposure was identified from generic names, brand names, development code names and the active-ingredient field. Pericardial events were defined by seven MedDRA preferred terms. We estimated reporting odds ratios (ROR), proportional reporting ratios (PRR), Bayesian information components (IC) and empirical Bayes geometric means (EBGM). We also examined myocarditis co-reporting, time trends, a comparison with other antineoplastic agents, a MedDRA query-based outcome, and 14 alternative definitions. Results. The analysis included 18,514,045 cases: 277,434 involved an ICI, 34,792 carried a pericardial term, and 1,680 had both. Pericardial events were reported disproportionately with ICIs (ROR 3.35 (95% CI 3.19 to 3.52); PRR 3.34; IC025 1.62). Eight of nine agents had a ROR above 1 (3.32 to 5.63). Among the most frequently reported terms, estimates were highest for cardiac tamponade (5.59 (95% CI 4.98 to 6.28)), followed by pericardial effusion (3.83 (95% CI 3.60 to 4.07)) and pericarditis (2.09 (95% CI 1.89 to 2.31)). After removing cases that also reported myocarditis, the ROR was 3.13 (95% CI 2.98 to 3.30). Most sensitivity analyses gave similar estimates (ROR 3.13 to 3.47); defining exposure by generic drug names alone, which identified only 44% of exposed cases, gave 3.99. Compared with cases naming other L01 antineoplastic agents, the ROR was 1.13 (95% CI 1.08 to 1.19): 1.28 (95% CI 1.20 to 1.36) for ICI-only cases and 0.96 (95% CI 0.89 to 1.04) when another antineoplastic was also named. The ICI-specific reporting odds ratio fell each quarter (odds ratio 0.977 per quarter, 95% CI 0.973 to 0.980). Conclusions. In FAERS, pericardial events were reported more often with ICIs than with other drugs across most agents and terms; however, incidence and causation cannot be determined. The excess over other antineoplastic agents was small, and reporting disproportionality declined over time. These findings support clinical awareness of pericardial disease in patients receiving ICIs and warrant study in data that can measure incidence.
- Open Access
- 1 June 2026
- Published by Wolters Kluwer Health in Neurosurgery Practice
- Vol. 7 (3) , e000252
Neurosurgical Care in Italy: A Comprehensive Review and Lessons for High-Income Nations
Italy's neurosurgical system provides valuable insights for developed nations seeking to optimize care delivery while managing aging populations and resource constraints. With approximately 1000 neurosurgeons (1.69 per 100 000 people) distributed across 141 neurosurgical divisions, Italy delivers equitable access through its National Health Service while demonstrating exceptional cost-effectiveness, with procedures averaging $11 907 compared with $24 754 in the United States. Italy has integrated cutting-edge technologies including virtual and augmented reality applications that reduce surgical errors by up to 36% in mixed-reality neuronavigation, alongside virtual reality–based rehabilitation programs improving cognitive function and pain management. The system's 77 active multidisciplinary teams optimize complex cases in neuro-oncology and pediatric neurosurgery, supported by systematic care improvements including the Homogeneous Waiting Group approach for clinical prioritization, digital preassessment tools, and tele-neuro-rehabilitation programs that reduce hospital readmissions. Structured follow-up care with standardized 3 to 4 month intervals demonstrates superior early recurrence detection compared with variable international practices. This report will delve in greater detail Italy's innovative approach to neurosurgical procedures, training, and educational methodologies that are producing better outcomes for patients and health care professionals.
- 1 June 2026
- Published by Wolters Kluwer Health in Neurosurgery Practice
- Vol. 7 (3) , e000252
Open AccessNeurosurgical Care in Italy: A Comprehensive Review and Lessons for High-Income Nations
Italy's neurosurgical system provides valuable insights for developed nations seeking to optimize care delivery while managing aging populations and resource constraints. With approximately 1000 neurosurgeons (1.69 per 100 000 people) distributed across 141 neurosurgical divisions, Italy delivers equitable access through its National Health Service while demonstrating exceptional cost-effectiveness, with procedures averaging $11 907 compared with $24 754 in the United States. Italy has integrated cutting-edge technologies including virtual and augmented reality applications that reduce surgical errors by up to 36% in mixed-reality neuronavigation, alongside virtual reality–based rehabilitation programs improving cognitive function and pain management. The system's 77 active multidisciplinary teams optimize complex cases in neuro-oncology and pediatric neurosurgery, supported by systematic care improvements including the Homogeneous Waiting Group approach for clinical prioritization, digital preassessment tools, and tele-neuro-rehabilitation programs that reduce hospital readmissions. Structured follow-up care with standardized 3 to 4 month intervals demonstrates superior early recurrence detection compared with variable international practices. This report will delve in greater detail Italy's innovative approach to neurosurgical procedures, training, and educational methodologies that are producing better outcomes for patients and health care professionals.
- Open Access
Automated Coronary Artery Disease Detection Using a CNN Model with Temporal Attention
I. A bstract: Coronary Artery Disease (CAD) is a leading cause of cardiovascular-related mortality and affects 20.5 million people in the United States and approximately 315 million people worldwide in 2022. The asymptomatic and progressive nature of CAD presents challenges for early diagnosis and timely intervention. Traditional diagnostic methods such angiography and stress tests are known to be resource-intensive and prone to human error. This calls for a need for automated and time-effective detection methods. In this paper, this paper introduces a novel approach to the diagnosis of CAD based on a Convolutional Neural Network (CNN) with a temporal attention mechanism. The model will be developed on an architecture that will automatically extract and emphasize critical features from sequential medical imaging data from coronary angiograms, allowing subtle signs of CAD to be easily spotted, which could not have been detected by convention. The temporal attention mechanism strengthens the ability of a model to focus on relevant temporal patterns, thus improving sensitivity and robustness in detecting CAD for various stages of the disease. Experimental validation on a large and diverse dataset demonstrates the efficacy of the proposed method, with significant improvements in both detection accuracy and processing time compared to traditional CNN architectures. The results of this study propose a scalable solution system for the diagnosis of CAD. This proposed system can be integrated into clinical workflows to assist healthcare professionals. Ultimately, this research contributes to the field of AI-driven healthcare solutions and has the potential to reduce the global burden of CAD through early automated detection.
Open AccessAutomated Coronary Artery Disease Detection Using a CNN Model with Temporal Attention
I. A bstract: Coronary Artery Disease (CAD) is a leading cause of cardiovascular-related mortality and affects 20.5 million people in the United States and approximately 315 million people worldwide in 2022. The asymptomatic and progressive nature of CAD presents challenges for early diagnosis and timely intervention. Traditional diagnostic methods such angiography and stress tests are known to be resource-intensive and prone to human error. This calls for a need for automated and time-effective detection methods. In this paper, this paper introduces a novel approach to the diagnosis of CAD based on a Convolutional Neural Network (CNN) with a temporal attention mechanism. The model will be developed on an architecture that will automatically extract and emphasize critical features from sequential medical imaging data from coronary angiograms, allowing subtle signs of CAD to be easily spotted, which could not have been detected by convention. The temporal attention mechanism strengthens the ability of a model to focus on relevant temporal patterns, thus improving sensitivity and robustness in detecting CAD for various stages of the disease. Experimental validation on a large and diverse dataset demonstrates the efficacy of the proposed method, with significant improvements in both detection accuracy and processing time compared to traditional CNN architectures. The results of this study propose a scalable solution system for the diagnosis of CAD. This proposed system can be integrated into clinical workflows to assist healthcare professionals. Ultimately, this research contributes to the field of AI-driven healthcare solutions and has the potential to reduce the global burden of CAD through early automated detection.
- Open Access
A Tabular Residual Neural Network for Diabetes Classification and Prediction
Diabetes Mellitus (DM) is a metabolic disorder characterized by hyperglycemia, with type 1 characterized as an autoimmune destruction of pancreatic beta cells and type 2 characterized by insulin resistance with progressive beta cell dysfunction. This study applied an existing binary classification algorithm (ALTARN) to accurately predict DM. ALTARN, as a tabular attention residual neural network, uses residual connection to find complex patterns present in tabular columns. We achieved an average training accuracy of 75.22%. Furthermore, a robust set of validation metrics was obtained via five-fold stratified cross-validation, yielding an average accuracy of 74.61%, an average precision of 72.36%, a mean recall of 79.69%, and a mean F1 score of 75.83%.
Open AccessA Tabular Residual Neural Network for Diabetes Classification and Prediction
Diabetes Mellitus (DM) is a metabolic disorder characterized by hyperglycemia, with type 1 characterized as an autoimmune destruction of pancreatic beta cells and type 2 characterized by insulin resistance with progressive beta cell dysfunction. This study applied an existing binary classification algorithm (ALTARN) to accurately predict DM. ALTARN, as a tabular attention residual neural network, uses residual connection to find complex patterns present in tabular columns. We achieved an average training accuracy of 75.22%. Furthermore, a robust set of validation metrics was obtained via five-fold stratified cross-validation, yielding an average accuracy of 74.61%, an average precision of 72.36%, a mean recall of 79.69%, and a mean F1 score of 75.83%.
- Open Access
- 24 October 2025
- Published by Springer Nature in Research Square
Frailty and Nutritional Risk as Predictors of Postoperative Outcomes in Arteriovenous Malformation Surgery
An analysis of 435 patients from the ACS-NQIP database was conducted in regards to AVM surgical patients with specified tiers for Risk Analysis Index (RAI), Geriatric Nutritional Risk Index (GNRI), Preoperative Acute Severe Condition (PACS), Modified Frailty Index-5 (mFI-5), American Society of Anesthesiologists (ASA), and Combined GNRI-ASA-RAI-PACS (CGARP) to evaluate 30 day outcomes for mortality, non-routine discharge, complications, and readmission/reoperation. A DeLong test was used to compare all indices against the novel compound score, and it was found that frailty and nutrition are significantly associated with post-operative outcomes, and that CGARP has superior discrimination in predicting mortality, eLOS, complications, and readmission due to its utilization of ASA,GNRI, RAI, and PACS.
- 24 October 2025
- Published by Springer Nature in Research Square
Open AccessFrailty and Nutritional Risk as Predictors of Postoperative Outcomes in Arteriovenous Malformation Surgery
An analysis of 435 patients from the ACS-NQIP database was conducted in regards to AVM surgical patients with specified tiers for Risk Analysis Index (RAI), Geriatric Nutritional Risk Index (GNRI), Preoperative Acute Severe Condition (PACS), Modified Frailty Index-5 (mFI-5), American Society of Anesthesiologists (ASA), and Combined GNRI-ASA-RAI-PACS (CGARP) to evaluate 30 day outcomes for mortality, non-routine discharge, complications, and readmission/reoperation. A DeLong test was used to compare all indices against the novel compound score, and it was found that frailty and nutrition are significantly associated with post-operative outcomes, and that CGARP has superior discrimination in predicting mortality, eLOS, complications, and readmission due to its utilization of ASA,GNRI, RAI, and PACS.
- Open Access
ALTARN: A Tabular Residual Neural Network for Alzheimer’s Disease Classification and Prediction
Early and accurate prediction of Alzheimer’s disease (AD) from accessible clinical data remains a significant challenge in healthcare. This study proposes ALTARN, a tabular attention residual neural network architecture for robust classification of AD through heterogeneous patient data from a publicly available dataset of 2149 subjects, with medical, demographic, and lifestyle variables organized as structured tabular data. With sigmoid attention mechanisms for the dynamic reweighing of input variables for each patient, deep residual connections capturing complex, and non-linear relationships in tabular features, we propose ALTARN-an early Alzheimer prediction tool. ALTARN achieved an average cross-validated training accuracy of roughly 92.73%, alongside robust validation metrics, including an average accuracy of 85.06%, average precision of 80.73%, mean recall of 76.18%, and a mean validation F1-score of 78.32% when evaluated through five-fold stratified validation. When tested against other approaches, ALTARN meets and also exceeds the performance of supervised deep learning models for non-imaging AD classification. This further illustrates that deep neural network based approaches with tabular attention offer a promising direction for interpretable diagnosis of AD via non-imaging medical data.
Open AccessALTARN: A Tabular Residual Neural Network for Alzheimer’s Disease Classification and Prediction
Early and accurate prediction of Alzheimer’s disease (AD) from accessible clinical data remains a significant challenge in healthcare. This study proposes ALTARN, a tabular attention residual neural network architecture for robust classification of AD through heterogeneous patient data from a publicly available dataset of 2149 subjects, with medical, demographic, and lifestyle variables organized as structured tabular data. With sigmoid attention mechanisms for the dynamic reweighing of input variables for each patient, deep residual connections capturing complex, and non-linear relationships in tabular features, we propose ALTARN-an early Alzheimer prediction tool. ALTARN achieved an average cross-validated training accuracy of roughly 92.73%, alongside robust validation metrics, including an average accuracy of 85.06%, average precision of 80.73%, mean recall of 76.18%, and a mean validation F1-score of 78.32% when evaluated through five-fold stratified validation. When tested against other approaches, ALTARN meets and also exceeds the performance of supervised deep learning models for non-imaging AD classification. This further illustrates that deep neural network based approaches with tabular attention offer a promising direction for interpretable diagnosis of AD via non-imaging medical data.
- Open Access
- 22 October 2025
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (1)
Hematologic cancers in the SAARC region: current burden in 2022 and projections to 2050
- 22 October 2025
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (1)
Open AccessHematologic cancers in the SAARC region: current burden in 2022 and projections to 2050
- Open Access
- 31 July 2025
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 37, e20250380
Understanding artificial intelligence in critical care: opportunities, risks, and practical applications
Artificial intelligence technologies are rapidly advancing and significantly impacting healthcare, particularly in critical care environments where rapid, precise decision-making is crucial. They promise reductions in clinical errors, enhanced diagnostic accuracy, optimized treatment plans, and better resource allocation. Artificial intelligence applications are widespread across medical fields, with numerous artificial intelligence/machine learning-enabled medical devices approved by […] ABSTRACT Artificial intelligence technologies are rapidly advancing and significantly impacting healthcare, particularly in critical care environments where rapid, precise decision-making is crucial. They promise reductions in clinical errors, enhanced diagnostic accuracy, optimized treatment plans, and better resource allocation. Artificial intelligence applications are widespread across medical fields, with numerous artificial intelligence/machine learning-enabled medical devices approved by […]
- 31 July 2025
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 37, e20250380
Open AccessUnderstanding artificial intelligence in critical care: opportunities, risks, and practical applications
Artificial intelligence technologies are rapidly advancing and significantly impacting healthcare, particularly in critical care environments where rapid, precise decision-making is crucial. They promise reductions in clinical errors, enhanced diagnostic accuracy, optimized treatment plans, and better resource allocation. Artificial intelligence applications are widespread across medical fields, with numerous artificial intelligence/machine learning-enabled medical devices approved by […] ABSTRACT Artificial intelligence technologies are rapidly advancing and significantly impacting healthcare, particularly in critical care environments where rapid, precise decision-making is crucial. They promise reductions in clinical errors, enhanced diagnostic accuracy, optimized treatment plans, and better resource allocation. Artificial intelligence applications are widespread across medical fields, with numerous artificial intelligence/machine learning-enabled medical devices approved by […]